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Abstract
Background: Adipocyte-derived leucine aminopeptidase (ALAP) is a recently identified member
of the M1 family of zinc-metallopeptidases and is thought to play a role in blood pressure control
through inactivation of angiotensin II and/or generation of bradykinin. The enzyme seems to be
particularly abundant in the heart. Recently, the Arg528-encoding allele of the ALAP gene was
shown to be associated with essential hypertension.
Methods: We evaluated the influence of this polymorphism on the change in left ventricular mass
index in 90 patients with essential hypertension and echocardiographically diagnosed left
ventricular hypertrophy, randomised in a double-blind study to receive treatment with either the
angiotensin II type I receptor antagonist irbesartan or the beta1-adrenoceptor blocker atenolol for
48 weeks. Genyotyping was performed using minisequencing.
Results: After adjustment for potential covariates (blood pressure and left ventricular mass index
at baseline, blood pressure change, age, sex, dose and added antihypertensive treatment), there
was a marked difference between the Arg/Arg and Lys/Arg genotypes in patients treated with
irbesartan; those with the Arg/Arg genotype responded on average with an almost two-fold greater
regression of left ventricular mass index than patients with the Lys/Arg genotype (-30.1 g/m2 [3.6]
vs -16.7 [4.5], p = 0.03).
Conclusions: The ALAP genotype seems to determine the degree of regression of left ventricular
hypertrophy during antihypertensive treatment with the angiotensin II type I receptor antagonist
irbesartan in patients with essential hypertension and left ventricular hypertrophy. This is the first
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report of a role for ALAP/aminopeptidases in left ventricular mass regulation, and suggests a new
potential target for antihypertensive drugs.
Background
Hypertension is associated with a number of adverse mor-
phologic and functional changes in the cardiovascular sys-
tem such as left ventricular (LV) hypertrophy, a condition
associated with an increased risk of both cardiovascular
morbidity and mortality and also all-cause mortality [1–
4]. The effects of angiotensin II on blood pressure and on
structural cardiac and vascular remodelling indicate that
the renin-angiotensin system plays an important part in
the development of LV hypertrophy. Most angiotensin II
is generated in two sequential steps: renin catalyzes the
conversion of angiotensinogen to angiotensin I, which is
subsequently hydrolyzed by angiotensin-converting
enzyme (ACE) to form angiotensin II [5].
ACE, however, not only generates angiotensin II but also
degrades bradykinin. Kinetic studies have shown that
bradykinin is the preferred ACE substrate [6]. Bradykinin
mediates important cardiovascular effects that may pro-
tect against LV hypertrophy. All components of a func-
tional bradykinin system are expressed in the heart, and
bradykinin clearly mediates important cardiovascular
effects, such as negative inotropism and inhibition of
myocardial growth [6]. For instance, a B2 bradykinin-
receptor antagonist significantly attenuated the antihyper-
tensive effect of ACE inhibitors in humans, and the cardi-
oprotective effect of ACE inhibitors was lost in B2
bradykinin-receptor knock-out mice [6]. It thus seems
probable that bradykinin is an important counteractive
substance of the cardiac effects of the renin-angiotensin
system.
Aminopeptidases play a role in the metabolism of several
peptides [7] that may be involved in blood pressure regu-
lation and the pathogenesis of hypertension [8,9]. Adi-
pocyte-derived leucine aminopeptidase (ALAP) has
recently been identified as a member of the M1 family of
zinc-metallopeptidases [10,11]. ALAP was shown to
hydrolyze a variety of bioactive peptides in vitro, includ-
ing angiotensin II and kallidin [10]. ALAP is widely
expressed in human tissues. Its presence in the cortex of
the kidney may be especially interesting due to the pres-
ence of kallikrein. It also seems to be particularly abun-
dant in the heart [12]. The enzyme is thought to play a
role in the regulation of blood pressure through inactiva-
tion of angiotensin II and/or generation of bradykinin
[10].
Recently, the Arg528 variant of the Lys528Arg (A1583G)
polymorphism in the ALAP gene was shown to be associ-
ated with essential hypertension [13]. Since ALAP seems
to be particularly abundant in the heart, it would seem
reasonable to believe that the enzyme could be involved
in the modulation of LV mass. No study has yet investi-
gated the effect of this polymorphism on the change in LV
mass during antihypertensive treatment. Therefore we
chose to study the relationship between this specific poly-
morphism and the change in LV mass index (LVMI) in
hypertensive patients with LV hypertrophy during antihy-
pertensive treatment with either the AT1-receptor antago-
nist irbesartan or the beta1-adrenoceptor blocker atenolol.
Methods
The subjects participated in the SILVHIA trial, which has
been described in detail earlier [14]. Briefly, Caucasian
men and women with mild-to-moderate essential hyper-
tension, and echocardiographically verified LV hypertro-
phy were enrolled, with the primary goal of evaluating the
efficacy of irbesartan compared to atenolol on blood pres-
sure reduction and regression of LV hypertrophy. LV
hypertrophy was considered present if LVMI was >131 g/
m2 for men and >100 g/m2 for women. The Penn conven-
tion was used for calculation of LV mass, which was cor-
rected for body mass index (LVMI). The inclusion criteria
constituted a diastolic blood pressure (DBP) of 90–115
mmHg. Secondary hypertension was excluded by means
of a physical examination and routine laboratory tests. All
antihypertensive agents were withdrawn before the start
of a 4–6 week, single-blind, placebo lead-in period, after
which the patients received either irbesartan 150 mg or
atenolol 50 mg once daily as monotherapy in a double-
blind fashion. The doses were doubled after six weeks if
DBP was ≥ 90 mmHg. If DBP remained ≥ 90 mmHg at
week 12, hydrochlorothiazide (12.5–25 mg once daily)
was added. At week 24, felodipine (5–10 mg once daily)
was added if required. In all, 101 patients completed the
whole 48 week study, for whom DNA and echocardio-
graphic data were available in 90. The appropriate ethics
committees approved the study, the participating patients
gave their informed consent, and the study was completed
in accordance with institutional guidelines.
Genomic DNA was extracted from EDTA-blood using spin
columns (QIAamp® DNA Blood Mini Kit, QIAGEN, Ger-
many). PCR was conducted using AmpliTaq™ Gold DNA
polymerase (Applied Biosystems, USA) with primers
described earlier[13] manufactured by Interactiva (The
Virtual Laboratory, Germany) with the exception of bioti-
nylation at the 5'-end of the forward primer. 50 µl reac-
tion volumes containing PCR Buffer II, 3.5 mmol/LBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/11
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MgCl2, 0.25 mmol/L of each dNTP, 0.4 µmol/L of each
primer, 1 U of Taq DNA polymerase and approximately
100 ng of genomic DNA were used. PCR conditions con-
sisted of an initial activation step at 95°C for 10 min, fol-
lowed by 40 cycles of 95°C for 30 s, 61°C for 30 s and
72°C for 60 s, after which a final elongation step at 72°C
for 10 min concluded the reaction (GeneAmp PCR system
9700, Applied Biosystems, USA). Genotyping for the
ALAP polymorphism was conducted with solid phase
minisequencing follwing a protocol described earlier [15–
17]. The detection primer used was 5'-GAA CAC TTG GAC
ACT GCA GA-3'.
Data are presented as mean values ± SE. The estimated
adjusted mean difference in LVMI change, as well as
echocardiographic measurements, at 48 weeks between
the genotypes (three categories) was calculated with the
GLM (general linear models) procedure of the SAS soft-
ware (SAS Institute, USA) for each treatment group. Two
different models were used: one univariate and one mul-
tivariate model including the potential covariates age,
systolic and diastolic blood pressure (SBP and DBP),
LVMI or the specific echocardiographic parameter at study
entry, dose of atenolol or irbesartan, change in SBP and
DBP (all continuous), sex, as well as the addition of
hydrochlorthiazide or felodipine (yes/no). BMI was also
included in the multivariate model for changes in
echocardiographic measurements. A p value of <0.05 was
considered significant.
Results
Genotype distribution (46 Arg/Arg [51%], 35 Lys/Arg
[39%], and 9 Lys/Lys [10%]) was consistent with Hardy-
Weinberg equilibrium. Fourty seven patients (22 Arg/Arg,
19 Lys/Arg and 6 Lys/Lys) were given atenolol and 43 (24
Arg/Arg, 16 Lys/Arg and 3 Lys/Lys) irbesartan. Among
patients given atenolol, 57% received 50 mg, 39% 100 mg
and the remaining either 75 mg or 25 mg. Among patients
given irbesartan, 66% received 300 mg, 29% 150 mg, and
the remaining either 75 or 225 mg. A total of 57% of the
patients required additional treatment with felodipine
and/or hydrochlorothiazide. Baseline characteristics of
the patients stratified by treatment and genotype are
shown in table 1. There were no significant differences
between the genotypes in any group, except for baseline
DBP in the atenolol group, where patients with the Lys/
Lys genotype had a significantly higher level than those
with the Lys/Arg genotype (p = 0.01),
As was previously shown in the SILVHIA trial [14], both
irbesartan and atenolol progressively reduced LVMI by 26
(p < 0.001) and 14 g/m2 (p < 0.001) (16 and 9%), respec-
tively, at week 48, with a greater reduction in the
irbesartan group (p = 0.02). After stratification by ALAP
Table 1: Baseline patient characteristics stratified by treatment and genotype.
Irbesartan Lys/Lys (n = 3) Lys/Arg (n = 16) Arg/Arg (n = 24)
Gender (male/female) 1/2 11/5 13/11
Age (years) 57.3 [4.1] 52.6 [1.6] 53.7 [1.8]
BMI (kg/m2) 26.8 [1.8] 27.2 [0.7] 27.0 [0.7]
SBP (mmHg) 159.6 [10.6] 161.7 [4.8] 164.0 [4.0]
DBP (mmHg) 105.6 [2.9] 104.1 [2.0] 104.2 [1.2]
IVS (mm) 1.2 [0.1] 1.4 [0.05] 1.4 [0.05]
PWT (mm) 1.0 [0.04] 1.1 [0.03] 1.1 [0.04]
LVEDD (mm) 4.9 [0.2] 5.1 [0.1] 5.1 [0.1]
LVMI (g/m2) 126.2 [7.6] 143.5 [5.0] 154.8 [8.5]
Atenolol Lys/Lys (n = 6) Lys/Arg (n = 19) Arg/Arg (n = 22)
Gender (male/female) 6/0 11/8 14/8
Age (years) 51.8 [3.5] 55.5 [1.9] 52.7 [1.8]
BMI (kg/m2) 26.9 [0.9] 26.9 [0.9] 27.8 [0.9]
SBP (mmHg) 170.1 [8.6] 159.8 [5.4] 154.0 [3.2]
DBP (mmHg) 109.0 [2.2] 99.8 [2.0] 102.6 [1.6]
IVS (mm) 1.3 [0.09] 1.3 [0.05] 1.3 [0.04]
PWT (mm) 1.0 [0.03] 1.0 [0.03] 1.1 [0.03]
LVEDD (mm) 5.6 [0.3] 5.1 [0.1] 5.1 [0.1]
LVMI (g/m2) 159.7 [12.5] 140.5 [5.5] 146.3 [5.6]
BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; IVS = intraventricular septum; PWT = posterior wall 
thickness; LVEDD = left ventricular end-diastolic diameter; LVMI = left ventricular mass index. Mean values ± SE.BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/11
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genotype, there was a statistically significant regression of
LVMI only among patients with the Arg/Arg genotype in
both treatment groups (-33.6 g/m2 [6.1] in the irbesartan
group and -15.5 g/m2 [3.0] in the atenolol group, p <
0.0001 for both), and among patients with the Lys/Arg
genotype in the irbesartan group (-14.9 g/m2 [5.6], p =
0.02). There were no statistically significant differences
between genotypes and change in intraventricular septum
and posterior wall thickness or left ventricular end diasto-
lic diameter in the two treatment groups (table 2). Overall
uni- and multivariate changes in LVMI and in blood pres-
sure change at 48 weeks, stratified by treatment and geno-
type, are shown in table 3. According to the multivariate
model there was a significant difference in LVMI change
between the Arg/Arg and Lys/Arg genotype among
patients given irbesartan (figure 1). Patients with the Arg/
Arg genotype responded with a greater regression of LVMI
than patients with the Lys/Arg genotype (-30.1 g/m2 [3.6]
vs -16.7 [4.5], p = 0.03). Patients with the Lys/Lys geno-
type were too few (n = 3) to allow statistical comparison
in the irbesartan group. No significant differences were
found between genotypes among patients given atenolol.
Nor were there any significant differences in blood pres-
sure change between genotypes in any treatment group at
48 weeks (table 3).
Discussion
To our knowledge, this is the first study investigating the
effect of the Lys528Arg polymorphism in the ALAP gene
on the change in LV mass during antihypertensive treat-
ment. Our results suggest that patients with hypertensive
LV hypertrophy that are homozygous for the Arg-encod-
ing allele respond with a greater reduction of LV mass to
the AT1 receptor antagonist irbesartan than patients with
the Lys/Arg phenotype. At present, there is no evidence
that this polymorphism causes functional alterations in
the ALAP protein. However, the Lys at amino acid 528 is
conserved in ALAP, leucyl/cystinyl aminopeptidase
(LNPEP), rat puromycin-insensitive leucyl-specific ami-
nopeptidase and mouse vascular endothelial growth fac-
tor (VEGF)-induced aminopeptidase [13]. Albeit,
conservation of an amino acid does not necessarily indi-
cate functional importance of the site. Recombinant
expression experiments comparing activities of the two
variants of the enzyme would elucidate functional altera-
tions caused by this polymorphism.
In one of the subgroups, the Arg/Arg genotype in the irbe-
sartan treatment group, baseline LVMI was not completely
normally distributed when normality was analyzed by the
Shapiro-Wilks test. This, however, did not affect our con-
Table 2: Change in echocardiographic measurements at 48 weeks stratified by treatment and genotype
Irbesartan Atenolol
Lys/Lys (n = 3) Lys/Arg (n = 16) Arg/Arg (n = 24) Lys/Lys (n = 6) Lys/Arg (n = 19) Arg/Arg (n = 22)
IVS (mm) -0.12 [0.1] -0.21 [0.04] -0.19 [0.04] -0.15 [0.06] -0.11 [0.04] -0.14 [0.03]
IVS (mm) – multivariate -0.11 [0.1] -0.22 [0.04] -0.18 [0.03] -0.20 [0.07] -0.14 [0.04] -0.099 [0.04]
PWT (mm) -0.043 [0.07] -0.055 [0.03] -0.13 [0.03] -0.11 [0.05] -0.041 [0.03] -0.13 [0.03]
PWT (mm) – multivariate -0.032 [0.07] -0.073 [0.03] -0.12 [0.02] -0.070 [0.06] -0.051 [0.03] -0.13 [0.03]
LVEDD (mm) 0.077 [0.2] 0.17 [0.09] -0.063 [0.07] -0.037 [0.1] 0.11 [0.07] 0.17 [0.07]
LVEDD (mm) – multivariate -0.13 [0.2] 0.15 [0.07] -0.029 [0.06] 0.016 [0.2] 0.11 [0.08] 0.17 [0.07]
IVS = intraventricular septum; PWT = posterior wall thickness; LVEDD = left ventricular end-diastolic diameter. Mean values ± SE.
Table 3: LVMI and blood pressure change at 48 weeks stratified by treatment and genotype 
Irbesartan Atenolol
Lys/Lys (n = 3) Lys/Arg (n = 16) Arg/Arg (n = 24) Lys/Lys (n = 6) Lys/Arg (n = 19) Arg/Arg (n = 22)
DBP change (mmHg) -14.8 [8.1] -18.2 [2.3] -19.5 [1.5] -19.6 [3.3] -12.8 [1.8] -17.5 [1.4]
DBP change (mmHg) -14.8 [8.1] -18.2 [2.3] -19.5 [1.5] -19.6 [3.3] -12.8 [1.8] -17.5 [1.4]
SBP change (mmHg) -9.1 [15.3] -26.3 [5.1] -31.5 [4.1] -27.1 [5.9] -19.3 [3.7] -21.2 [3.3]
LVMI change (g/m2) -12.2 [15.3] -14.9 [6.6] -33.6 [5.4] -25.2 [8.6] -9.0 [4.8] -15.5 [4.7]
LVMI change (g/m2) – multivariate -31.6 [11.6] -16.7 [4.5] -30.1 [3.6] * -22.2 [9.6] -13.3 [5.0] -12.6 [4.5]
SBP = systolic blood pressure; DBP = diastolic blood pressure; LVMI = left ventricular mass index. Mean values ± SE. * p = 0.03 between Arg/Arg 
and Lys/Arg.BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/11
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clusions. There was no significant baseline difference in
LVMI between the Arg/Arg and Arg/Lys group given irbe-
sartan. The p value for a difference between the groups
with a t-test was 0.32 for the original data and 0.43 for the
log-transformed data. The p values for the univariate and
the multivariate adjusted difference in mean LVMI differ-
ence after 48 weeks between the groups remained nearly
identical after log transformation of the LVMI data, and
therefore skewness can not explain our finding. The LVMI
data in the other subgroups displayed a normal distribu-
tion by the original data.
The hypothesis raised by Yamamoto et al [13] was that a
reduced ALAP activity in the Arg528 form compared with
the Lys528 form resulted in high blood pressure and
hypertension due to insufficient inactivation of angi-
otensin II or decreased generation of bradykinin, or both.
This may imply that patients homozygous for the Arg-
encoding allele benefit more from treatment with an AT1
receptor antagonist than a beta1-adrenoceptor blocker,
which was the case in our study. The results also suggest a
role for ALAP/aminopeptidases in the regulation of LV
mass, which is in accordance with Hattori et al that ALAP
is particularly abundant in the heart. If so, aminopepti-
dases might be a new potential target for antihypertensive
drugs.
The major limitation of the present study is the small
number of subjects not allowing us to evaluate the regres-
sion of LVMI among those with the more uncommon Lys/
Lys genotype in the irbesartan group. Also, the possibility
that the studied polymorphism could be in linkage dise-
quilibrium with another polymorphism cannot be ruled
out. The strength of the study, on the other hand, is that
the subjects represent a clinically well-characterised
group, randomised to treatment in a prospective, double-
blind trial. It would be of great interest to study the impact
of this polymorphism on the incidence of cardiovascular
end-points during AT1-receptor antagonist treatment in
larger trials.
Conclusions
Our results suggest that patients with essential hyperten-
sion and LV hypertrophy and who carry the Arg528Arg
ALAP phenotype respond with a greater regression of
LVMI during treatment with the AT1 receptor antagonist
irbesartan than those with the Lys528Arg genotype. To
our knowledge, our results are the first to suggest that
ALAP/aminopeptidases may play a role in the control of
LV mass. This might be a potential target for new antihy-
pertensive drugs.
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